nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftaroline fosamil—Neutropenia—Vinorelbine—ovarian cancer	0.00685	0.00685	CcSEcCtD
Ceftaroline fosamil—Transaminases increased—Doxorubicin—ovarian cancer	0.00683	0.00683	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Melphalan—ovarian cancer	0.00671	0.00671	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Melphalan—ovarian cancer	0.00663	0.00663	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Paclitaxel—ovarian cancer	0.00662	0.00662	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Melphalan—ovarian cancer	0.00658	0.00658	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Vinorelbine—ovarian cancer	0.00653	0.00653	CcSEcCtD
Ceftaroline fosamil—Infestation—Vinorelbine—ovarian cancer	0.00653	0.00653	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Topotecan—ovarian cancer	0.00622	0.00622	CcSEcCtD
Ceftaroline fosamil—Anaemia—Chlorambucil—ovarian cancer	0.0062	0.0062	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Topotecan—ovarian cancer	0.00619	0.00619	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Vinorelbine—ovarian cancer	0.00618	0.00618	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Melphalan—ovarian cancer	0.00606	0.00606	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Topotecan—ovarian cancer	0.00597	0.00597	CcSEcCtD
Ceftaroline fosamil—Convulsion—Chlorambucil—ovarian cancer	0.00581	0.00581	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Docetaxel—ovarian cancer	0.00561	0.00561	CcSEcCtD
Ceftaroline fosamil—Anaemia—Topotecan—ovarian cancer	0.00552	0.00552	CcSEcCtD
Ceftaroline fosamil—Anaemia—Melphalan—ovarian cancer	0.0054	0.0054	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00536	0.00536	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Vinorelbine—ovarian cancer	0.00532	0.00532	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Vinorelbine—ovarian cancer	0.0053	0.0053	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Paclitaxel—ovarian cancer	0.00519	0.00519	CcSEcCtD
Ceftaroline fosamil—Erythema—Vinorelbine—ovarian cancer	0.00511	0.00511	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Vinorelbine—ovarian cancer	0.00511	0.00511	CcSEcCtD
Ceftaroline fosamil—Convulsion—Melphalan—ovarian cancer	0.00506	0.00506	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00505	0.00505	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00494	0.00494	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Topotecan—ovarian cancer	0.00487	0.00487	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Topotecan—ovarian cancer	0.00478	0.00478	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Melphalan—ovarian cancer	0.00477	0.00477	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Topotecan—ovarian cancer	0.00477	0.00477	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Topotecan—ovarian cancer	0.00473	0.00473	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00472	0.00472	CcSEcCtD
Ceftaroline fosamil—Anaemia—Vinorelbine—ovarian cancer	0.00472	0.00472	CcSEcCtD
Ceftaroline fosamil—Pain—Chlorambucil—ovarian cancer	0.00468	0.00468	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Melphalan—ovarian cancer	0.00467	0.00467	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Melphalan—ovarian cancer	0.00463	0.00463	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Paclitaxel—ovarian cancer	0.00461	0.00461	CcSEcCtD
Ceftaroline fosamil—Palpitations—Vinorelbine—ovarian cancer	0.00451	0.00451	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00447	0.00447	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Paclitaxel—ovarian cancer	0.00445	0.00445	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Epirubicin—ovarian cancer	0.00441	0.00441	CcSEcCtD
Ceftaroline fosamil—Infestation—Paclitaxel—ovarian cancer	0.00439	0.00439	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Paclitaxel—ovarian cancer	0.00439	0.00439	CcSEcCtD
Ceftaroline fosamil—Urticaria—Chlorambucil—ovarian cancer	0.00435	0.00435	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Chlorambucil—ovarian cancer	0.00433	0.00433	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Chlorambucil—ovarian cancer	0.00433	0.00433	CcSEcCtD
Ceftaroline fosamil—Renal failure—Paclitaxel—ovarian cancer	0.00432	0.00432	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00432	0.00432	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00421	0.00421	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00417	0.00417	CcSEcCtD
Ceftaroline fosamil—Pain—Topotecan—ovarian cancer	0.00417	0.00417	CcSEcCtD
Ceftaroline fosamil—Constipation—Topotecan—ovarian cancer	0.00417	0.00417	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.00416	0.00416	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00412	0.00412	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Vinorelbine—ovarian cancer	0.00409	0.00409	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Doxorubicin—ovarian cancer	0.00408	0.00408	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00408	0.00408	CcSEcCtD
Ceftaroline fosamil—Pain—Melphalan—ovarian cancer	0.00408	0.00408	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Vinorelbine—ovarian cancer	0.00405	0.00405	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Chlorambucil—ovarian cancer	0.00403	0.00403	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Paclitaxel—ovarian cancer	0.00402	0.00402	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Topotecan—ovarian cancer	0.00398	0.00398	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Docetaxel—ovarian cancer	0.00391	0.00391	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Paclitaxel—ovarian cancer	0.0039	0.0039	CcSEcCtD
Ceftaroline fosamil—Pruritus—Chlorambucil—ovarian cancer	0.00387	0.00387	CcSEcCtD
Ceftaroline fosamil—Urticaria—Topotecan—ovarian cancer	0.00387	0.00387	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Paclitaxel—ovarian cancer	0.00387	0.00387	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Topotecan—ovarian cancer	0.00385	0.00385	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Topotecan—ovarian cancer	0.00385	0.00385	CcSEcCtD
Ceftaroline fosamil—Urticaria—Melphalan—ovarian cancer	0.00379	0.00379	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Epirubicin—ovarian cancer	0.00378	0.00378	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Chlorambucil—ovarian cancer	0.00374	0.00374	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Docetaxel—ovarian cancer	0.00372	0.00372	CcSEcCtD
Ceftaroline fosamil—Infestation—Docetaxel—ovarian cancer	0.00372	0.00372	CcSEcCtD
Ceftaroline fosamil—Renal failure—Docetaxel—ovarian cancer	0.00366	0.00366	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.0036	0.0036	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Topotecan—ovarian cancer	0.00359	0.00359	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Paclitaxel—ovarian cancer	0.00358	0.00358	CcSEcCtD
Ceftaroline fosamil—Constipation—Vinorelbine—ovarian cancer	0.00356	0.00356	CcSEcCtD
Ceftaroline fosamil—Pain—Vinorelbine—ovarian cancer	0.00356	0.00356	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Paclitaxel—ovarian cancer	0.00356	0.00356	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00352	0.00352	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Melphalan—ovarian cancer	0.00351	0.00351	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Doxorubicin—ovarian cancer	0.0035	0.0035	CcSEcCtD
Ceftaroline fosamil—Vomiting—Chlorambucil—ovarian cancer	0.00348	0.00348	CcSEcCtD
Ceftaroline fosamil—Pruritus—Topotecan—ovarian cancer	0.00345	0.00345	CcSEcCtD
Ceftaroline fosamil—Erythema—Paclitaxel—ovarian cancer	0.00343	0.00343	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Paclitaxel—ovarian cancer	0.00343	0.00343	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00341	0.00341	CcSEcCtD
Ceftaroline fosamil—Pruritus—Melphalan—ovarian cancer	0.00337	0.00337	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Docetaxel—ovarian cancer	0.00334	0.00334	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Topotecan—ovarian cancer	0.00333	0.00333	CcSEcCtD
Ceftaroline fosamil—Urticaria—Vinorelbine—ovarian cancer	0.00331	0.00331	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Docetaxel—ovarian cancer	0.0033	0.0033	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Vinorelbine—ovarian cancer	0.00329	0.00329	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Vinorelbine—ovarian cancer	0.00329	0.00329	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Docetaxel—ovarian cancer	0.00328	0.00328	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Melphalan—ovarian cancer	0.00326	0.00326	CcSEcCtD
Ceftaroline fosamil—Nausea—Chlorambucil—ovarian cancer	0.00325	0.00325	CcSEcCtD
Ceftaroline fosamil—Dizziness—Topotecan—ovarian cancer	0.00322	0.00322	CcSEcCtD
Ceftaroline fosamil—Anaemia—Paclitaxel—ovarian cancer	0.00317	0.00317	CcSEcCtD
Ceftaroline fosamil—Vomiting—Topotecan—ovarian cancer	0.0031	0.0031	CcSEcCtD
Ceftaroline fosamil—Rash—Topotecan—ovarian cancer	0.00307	0.00307	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Vinorelbine—ovarian cancer	0.00307	0.00307	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Topotecan—ovarian cancer	0.00307	0.00307	CcSEcCtD
Ceftaroline fosamil—Headache—Topotecan—ovarian cancer	0.00305	0.00305	CcSEcCtD
Ceftaroline fosamil—Palpitations—Paclitaxel—ovarian cancer	0.00303	0.00303	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Docetaxel—ovarian cancer	0.00303	0.00303	CcSEcCtD
Ceftaroline fosamil—Vomiting—Melphalan—ovarian cancer	0.00303	0.00303	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Docetaxel—ovarian cancer	0.00302	0.00302	CcSEcCtD
Ceftaroline fosamil—Rash—Melphalan—ovarian cancer	0.00301	0.00301	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Melphalan—ovarian cancer	0.003	0.003	CcSEcCtD
Ceftaroline fosamil—Convulsion—Paclitaxel—ovarian cancer	0.00298	0.00298	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Epirubicin—ovarian cancer	0.00297	0.00297	CcSEcCtD
Ceftaroline fosamil—Pruritus—Vinorelbine—ovarian cancer	0.00295	0.00295	CcSEcCtD
Ceftaroline fosamil—Erythema—Docetaxel—ovarian cancer	0.00291	0.00291	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Docetaxel—ovarian cancer	0.00291	0.00291	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.0029	0.0029	CcSEcCtD
Ceftaroline fosamil—Nausea—Topotecan—ovarian cancer	0.00289	0.00289	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Vinorelbine—ovarian cancer	0.00285	0.00285	CcSEcCtD
Ceftaroline fosamil—Nausea—Melphalan—ovarian cancer	0.00283	0.00283	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Paclitaxel—ovarian cancer	0.0028	0.0028	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Epirubicin—ovarian cancer	0.00279	0.00279	CcSEcCtD
Ceftaroline fosamil—Dizziness—Vinorelbine—ovarian cancer	0.00276	0.00276	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Paclitaxel—ovarian cancer	0.00275	0.00275	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Doxorubicin—ovarian cancer	0.00275	0.00275	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00274	0.00274	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Paclitaxel—ovarian cancer	0.00272	0.00272	CcSEcCtD
Ceftaroline fosamil—Anaemia—Docetaxel—ovarian cancer	0.00269	0.00269	CcSEcCtD
Ceftaroline fosamil—Vomiting—Vinorelbine—ovarian cancer	0.00265	0.00265	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Epirubicin—ovarian cancer	0.00263	0.00263	CcSEcCtD
Ceftaroline fosamil—Rash—Vinorelbine—ovarian cancer	0.00263	0.00263	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Vinorelbine—ovarian cancer	0.00262	0.00262	CcSEcCtD
Ceftaroline fosamil—Headache—Vinorelbine—ovarian cancer	0.00261	0.00261	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Doxorubicin—ovarian cancer	0.00258	0.00258	CcSEcCtD
Ceftaroline fosamil—Palpitations—Docetaxel—ovarian cancer	0.00257	0.00257	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Epirubicin—ovarian cancer	0.00254	0.00254	CcSEcCtD
Ceftaroline fosamil—Convulsion—Docetaxel—ovarian cancer	0.00252	0.00252	CcSEcCtD
Ceftaroline fosamil—Infestation—Epirubicin—ovarian cancer	0.00251	0.00251	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Epirubicin—ovarian cancer	0.00251	0.00251	CcSEcCtD
Ceftaroline fosamil—Nausea—Vinorelbine—ovarian cancer	0.00248	0.00248	CcSEcCtD
Ceftaroline fosamil—Renal failure—Epirubicin—ovarian cancer	0.00247	0.00247	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00246	0.00246	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Doxorubicin—ovarian cancer	0.00244	0.00244	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00242	0.00242	CcSEcCtD
Ceftaroline fosamil—Pain—Paclitaxel—ovarian cancer	0.0024	0.0024	CcSEcCtD
Ceftaroline fosamil—Constipation—Paclitaxel—ovarian cancer	0.0024	0.0024	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Epirubicin—ovarian cancer	0.00238	0.00238	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Docetaxel—ovarian cancer	0.00238	0.00238	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Doxorubicin—ovarian cancer	0.00235	0.00235	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Docetaxel—ovarian cancer	0.00233	0.00233	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Docetaxel—ovarian cancer	0.00233	0.00233	CcSEcCtD
Ceftaroline fosamil—Infestation—Doxorubicin—ovarian cancer	0.00232	0.00232	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Doxorubicin—ovarian cancer	0.00232	0.00232	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Docetaxel—ovarian cancer	0.00231	0.00231	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Epirubicin—ovarian cancer	0.0023	0.0023	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00229	0.00229	CcSEcCtD
Ceftaroline fosamil—Renal failure—Doxorubicin—ovarian cancer	0.00229	0.00229	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Epirubicin—ovarian cancer	0.00226	0.00226	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Epirubicin—ovarian cancer	0.00223	0.00223	CcSEcCtD
Ceftaroline fosamil—Urticaria—Paclitaxel—ovarian cancer	0.00223	0.00223	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Paclitaxel—ovarian cancer	0.00222	0.00222	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Paclitaxel—ovarian cancer	0.00222	0.00222	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Epirubicin—ovarian cancer	0.00221	0.00221	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.0022	0.0022	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Doxorubicin—ovarian cancer	0.00212	0.00212	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Doxorubicin—ovarian cancer	0.00209	0.00209	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Paclitaxel—ovarian cancer	0.00206	0.00206	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Doxorubicin—ovarian cancer	0.00206	0.00206	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Epirubicin—ovarian cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Doxorubicin—ovarian cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Epirubicin—ovarian cancer	0.00204	0.00204	CcSEcCtD
Ceftaroline fosamil—Constipation—Docetaxel—ovarian cancer	0.00203	0.00203	CcSEcCtD
Ceftaroline fosamil—Pain—Docetaxel—ovarian cancer	0.00203	0.00203	CcSEcCtD
Ceftaroline fosamil—Pruritus—Paclitaxel—ovarian cancer	0.00198	0.00198	CcSEcCtD
Ceftaroline fosamil—Erythema—Epirubicin—ovarian cancer	0.00196	0.00196	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Epirubicin—ovarian cancer	0.00196	0.00196	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00194	0.00194	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Paclitaxel—ovarian cancer	0.00192	0.00192	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Doxorubicin—ovarian cancer	0.00189	0.00189	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Doxorubicin—ovarian cancer	0.00188	0.00188	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Docetaxel—ovarian cancer	0.00188	0.00188	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Docetaxel—ovarian cancer	0.00188	0.00188	CcSEcCtD
Ceftaroline fosamil—Dizziness—Paclitaxel—ovarian cancer	0.00185	0.00185	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Doxorubicin—ovarian cancer	0.00182	0.00182	CcSEcCtD
Ceftaroline fosamil—Erythema—Doxorubicin—ovarian cancer	0.00182	0.00182	CcSEcCtD
Ceftaroline fosamil—Anaemia—Epirubicin—ovarian cancer	0.00181	0.00181	CcSEcCtD
Ceftaroline fosamil—Vomiting—Paclitaxel—ovarian cancer	0.00178	0.00178	CcSEcCtD
Ceftaroline fosamil—Rash—Paclitaxel—ovarian cancer	0.00177	0.00177	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Paclitaxel—ovarian cancer	0.00177	0.00177	CcSEcCtD
Ceftaroline fosamil—Headache—Paclitaxel—ovarian cancer	0.00176	0.00176	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Docetaxel—ovarian cancer	0.00175	0.00175	CcSEcCtD
Ceftaroline fosamil—Palpitations—Epirubicin—ovarian cancer	0.00173	0.00173	CcSEcCtD
Ceftaroline fosamil—Convulsion—Epirubicin—ovarian cancer	0.0017	0.0017	CcSEcCtD
Ceftaroline fosamil—Pruritus—Docetaxel—ovarian cancer	0.00168	0.00168	CcSEcCtD
Ceftaroline fosamil—Anaemia—Doxorubicin—ovarian cancer	0.00168	0.00168	CcSEcCtD
Ceftaroline fosamil—Nausea—Paclitaxel—ovarian cancer	0.00166	0.00166	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00166	0.00166	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Docetaxel—ovarian cancer	0.00163	0.00163	CcSEcCtD
Ceftaroline fosamil—Palpitations—Doxorubicin—ovarian cancer	0.00161	0.00161	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Epirubicin—ovarian cancer	0.0016	0.0016	CcSEcCtD
Ceftaroline fosamil—Convulsion—Doxorubicin—ovarian cancer	0.00157	0.00157	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Epirubicin—ovarian cancer	0.00157	0.00157	CcSEcCtD
Ceftaroline fosamil—Dizziness—Docetaxel—ovarian cancer	0.00157	0.00157	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Epirubicin—ovarian cancer	0.00157	0.00157	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Epirubicin—ovarian cancer	0.00156	0.00156	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00154	0.00154	CcSEcCtD
Ceftaroline fosamil—Vomiting—Docetaxel—ovarian cancer	0.00151	0.00151	CcSEcCtD
Ceftaroline fosamil—Rash—Docetaxel—ovarian cancer	0.0015	0.0015	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Docetaxel—ovarian cancer	0.0015	0.0015	CcSEcCtD
Ceftaroline fosamil—Headache—Docetaxel—ovarian cancer	0.00149	0.00149	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Doxorubicin—ovarian cancer	0.00148	0.00148	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Doxorubicin—ovarian cancer	0.00145	0.00145	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00145	0.00145	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Doxorubicin—ovarian cancer	0.00144	0.00144	CcSEcCtD
Ceftaroline fosamil—Nausea—Docetaxel—ovarian cancer	0.00141	0.00141	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00138	0.00138	CcSEcCtD
Ceftaroline fosamil—Constipation—Epirubicin—ovarian cancer	0.00137	0.00137	CcSEcCtD
Ceftaroline fosamil—Pain—Epirubicin—ovarian cancer	0.00137	0.00137	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00131	0.00131	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Urticaria—Epirubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Constipation—Doxorubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Pain—Doxorubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Epirubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Epirubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00121	0.00121	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Epirubicin—ovarian cancer	0.00118	0.00118	CcSEcCtD
Ceftaroline fosamil—Urticaria—Doxorubicin—ovarian cancer	0.00118	0.00118	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Doxorubicin—ovarian cancer	0.00117	0.00117	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Doxorubicin—ovarian cancer	0.00117	0.00117	CcSEcCtD
Ceftaroline fosamil—Pruritus—Epirubicin—ovarian cancer	0.00113	0.00113	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Epirubicin—ovarian cancer	0.0011	0.0011	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Doxorubicin—ovarian cancer	0.00109	0.00109	CcSEcCtD
Ceftaroline fosamil—Dizziness—Epirubicin—ovarian cancer	0.00106	0.00106	CcSEcCtD
Ceftaroline fosamil—Pruritus—Doxorubicin—ovarian cancer	0.00105	0.00105	CcSEcCtD
Ceftaroline fosamil—Vomiting—Epirubicin—ovarian cancer	0.00102	0.00102	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Doxorubicin—ovarian cancer	0.00101	0.00101	CcSEcCtD
Ceftaroline fosamil—Rash—Epirubicin—ovarian cancer	0.00101	0.00101	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Epirubicin—ovarian cancer	0.00101	0.00101	CcSEcCtD
Ceftaroline fosamil—Headache—Epirubicin—ovarian cancer	0.001	0.001	CcSEcCtD
Ceftaroline fosamil—Dizziness—Doxorubicin—ovarian cancer	0.00098	0.00098	CcSEcCtD
Ceftaroline fosamil—Nausea—Epirubicin—ovarian cancer	0.000952	0.000952	CcSEcCtD
Ceftaroline fosamil—Vomiting—Doxorubicin—ovarian cancer	0.000943	0.000943	CcSEcCtD
Ceftaroline fosamil—Rash—Doxorubicin—ovarian cancer	0.000935	0.000935	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Doxorubicin—ovarian cancer	0.000934	0.000934	CcSEcCtD
Ceftaroline fosamil—Headache—Doxorubicin—ovarian cancer	0.000929	0.000929	CcSEcCtD
Ceftaroline fosamil—Nausea—Doxorubicin—ovarian cancer	0.000881	0.000881	CcSEcCtD
